PDF(Pubmed)
Abstract：
Background: This study aimed to determine the cumulative prevalence of prolonged gastrointestinal (GI) symptoms, including nausea, vomiting, diarrhea, lack of appetite, abdominal pain, and dysgeusia, in survivors of both mild and severe COVID-19 worldwide and to discuss the potential pathogenesis. Methods: Three databases (PubMed, Scopus, and Web of Science) were searched for relevant articles up to January 30, 2021. Data on study characteristics, clinical characteristics during follow-up, the number of patients with prolonged GI symptoms, and total number of COVID-19 survivors were retrieved according to PRISMA guidelines. The quality of eligible studies was assessed using the Newcastle-Ottawa scale. The pooled prevalence of specific prolonged GI symptoms was calculated and the association between COVID-19 severity and the occurrence of prolonged GI symptoms was assessed if appropriate. Results: The global prevalence of prolonged nausea was 3.23% (95% CI: 0.54%-16.53%) among 527 COVID-19 survivors. Vomiting persisted in 93 of 2,238 COVID-19 survivors (3.19%, 95% CI: 1.62%-6.17%) and prolonged diarrhea was found in 34 of 1,073 survivors (4.12%, 95% CI: 1.07%-14.64%). A total of 156 patients among 2,238 COVID-19 survivors (4.41%, 95% CI: 1.91%-9.94%) complained of persistent decreased or loss of appetite. The cumulative prevalence of prolonged abdominal pain was 1.68% (95% CI: 0.84%-3.32%), whereas persistent dysgeusia was identified in 130 cases among 1,887 COVID-19 survivors (7.04%, 95% CI: 5.96%-8.30%). Data was insufficient to assess the relationship between COVID-19 severity and the occurrence of all prolonged GI symptoms. Conclusion: Persistent GI symptoms among COVID-19 survivors after discharge or recovery raises a concern regarding the long-term impact of the COVID-19 infection on the quality of life of the survivors. Despite several potential explanations proposed, studies that aim to follow patients after recovery from COVID-19 and determine the pathogenesis of the prolonged symptoms of COVID-19 survivors are warranted. PROSPERO registration: CRD42021239187.
摘要：
背景：本研究旨在确定长期胃肠道（GI）症状的累积患病率，包括恶心,呕吐,腹泻,缺乏食欲,腹痛,和味觉障碍,在全世界轻度和重度COVID-19的幸存者中，并讨论潜在的发病机制。方法：三个数据库(PubMed，Scopus,和WebofScience)搜索了截至2021年1月30日的相关文章。有关研究特征的数据，随访期间的临床特征，胃肠道症状延长的患者数量，并根据PRISMA指南检索COVID-19幸存者总数。使用纽卡斯尔-渥太华量表评估合格研究的质量。计算特定延长胃肠道症状的合并患病率，并酌情评估COVID-19严重程度与延长胃肠道症状发生之间的关系。结果：在527名COVID-19幸存者中，长期恶心的全球患病率为3.23％（95％CI：0.54％-16.53％）。在2,238名COVID-19幸存者中，有93名持续呕吐(3.19%，95％CI：1.62％-6.17％），在1,073名幸存者中有34名发现了长期腹泻（4.12％，95%CI：1.07%-14.64%）。在2,238例COVID-19幸存者中，共有156例患者（4.41%，95%CI：1.91%-9.94%）抱怨持续下降或食欲不振。长期腹痛的累积患病率为1.68%(95%CI:0.84%-3.32%),而在1,887名COVID-19幸存者中，有130例患者发现了持续性味觉障碍(7.04%，95%CI：5.96%-8.30%）。数据不足以评估COVID-19严重程度与所有延长胃肠道症状发生之间的关系。结论：出院或康复后COVID-19幸存者的持续胃肠道症状引起了人们对COVID-19感染对幸存者生活质量的长期影响的担忧。尽管提出了几种潜在的解释，有必要进行旨在追踪COVID-19康复后的患者并确定COVID-19幸存者长期症状的发病机制的研究。PROSPERO注册：CRD42021239187。
